Home
Country selector

MET Targeting

Oncogenic Signaling

MET targeting

MET signaling is critical in normal biological processes. It activates downstream signaling pathways, including RAS/ERK/MAPK, PI3K/AKT, and JAK/STAT, which drive cell proliferation, motility, and apoptosis. Dysregulation of the MET pathway (for example MET mutations and amplifications) can drive cancer cell proliferation, survival, invasion, and metastasis.1

Tepotinib – MET kinase inhibitor

Tepotinib is a small-molecule inhibitor of the MET receptor tyrosine kinase. Alterations of the MET signaling pathway are found in various cancer types, and are thought to correlate with aggressive tumor behavior and poor clinical prognosis.1

VISION2 (NCT02864992)

A Phase 2 single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 skipping alterations or MET amplification.

INSIGHT 23 (NCT03940703)

A Phase 2 clinical trial to investigate tepotinib combined with osimertinib in patients with osimertinib-resistant, MET-amplified, EGFR-mutant NSCLC.

Targeting MET

Are you interested in learning more about a clinical trial program investigating the inhibition of oncogenic signaling caused by MET (gene) alterations?

Learn more about our clinical trials

The investigational compound combinations in the INSIGHT 2 trial are not approved by any health authority. Safety and efficacy have not been established.

AKT, protein kinase B; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; MET, mesenchymal epithelial transition factor; NSCLC, non-small cell lung cancer, PI3K; phosphatidylinositol 3 kinase; RAS; rat sarcoma, STAT; signal transducers and activators of transcription.

  1. Wu Y-L, Soo RA, Locatelli G, Stammberger U, Scagliotti G, Park K. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? Cancer Treat Rev. 2017;61:70-81.
  2. Tepotinib phase II in NSCLC harboring MET alterations (VISION). ClinicalTrials.gov identifier: NCT02864992. Updated December 1, 2023. Accessed December 1, 2023. https://www.clinicaltrials.gov/ct2/show/NCT02864992 
  3. A study of tepotinib plus osimertinib in osimertinib relapsed MET amplified NSCLC (INSIGHT 2). ClinicalTrials.gov identifier: NCT03940703. Updated November 30, 2023. Accessed December 1, 2023. https://www.clinicaltrials.gov/ct2/show/NCT03940703

GL-MULO-00164 | January 2024

This website is an international information resource intended only for Healthcare Professionals who are licensed to practice outside the U.S., Canada, and Puerto Rico.

The information on this site is intended for educational purposes.

Connect with us

Find the Healthcare Business of Merck on:

©2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. Registered address: Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

GL-MULO-00155 | November 2023

Cookie Disclaimer

We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.

ACCEPT COOKIES
Your settings for the cookies

These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content. 

These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.

These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.

By clicking this link, you are leaving MerckGroupOncology.com. Please, note that this link will take you to a website оn which different Privacy Policy and Conditions may apply. Merck accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Continue
Go Back

Welcome to Merck Healthcare!

Help us direct you to the right information by selecting one of the following options:

I'm a Healthcare Professional

I'm NOT a Healthcare Professional